- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
March 10th, 2008
In a chemist's version of a winning PowerBall ticket, Richard Silverman's discovery eventually became a blockbuster drug that showered him and Northwestern University with more than $700 million in royalties.
Still, there was disappointment along the way. Once Pfizer Inc., the giant pharmaceutical concern, took control of the drug's development, Silverman was pushed aside.
"I was an outsider," said Silverman, 61. "There was no talk with their scientists. No comments. They had a launch party for the drug, and I asked to come. Nope. No party for me. They take your stuff and tell you to go away."
While it is common for university professors in places like California's Silicon Valley and Boston's Highway 128 to commercialize their research, it is less common in the Midwest, said Jon Wasserman, a Chicago-based attorney specializing in nanotechnology issues.
|Related News Press|
News and information
Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Quantum obstacle course changes material from superconductor to insulator December 1st, 2016
Throwing new light on printed organic solar cells December 1st, 2016